{
    "name": "orlistat",
    "comment": "Rx, OTC",
    "other_names": [
        "Alli",
        "Xenical"
    ],
    "classes": [
        "Gastrointestinal Agents",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/alli-xenical-orlistat-342068",
    "pregnancy": {
        "common": [
            "Pregnancy Category: X; weight loss offers no potential benefit to a pregnant woman and may result in fetal harm; a minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese",
            "Lactation: Not recommended; not known if orlistat is distributed in breast milk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Not recommended; not known if orlistat is distributed in breast milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pregnancy",
                "Chronic malabsorption syndrome",
                "Cholestasis",
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "If a meal is missed or contains no fat, dose should be omitted",
                "Daily fat intake (30% of calories), carbohydrate, and protein should be evenly distributed over 3 main meals",
                "Multivitamin supplement (including vitamin A, D, E, K) is recommended; supplement should be taken once a day at least 2 hours before or after the administration of orlistat, such as at bedtime",
                "Postmarketing reports of severe liver injury with hepatocellular necrosis or acute hepatic failure with some cases resulting in liver transplant or death; patients should be instructed to report any symptoms of hepatic dysfunction (anorexia, pruritus, jaundice, dark urine, light-colored stools, or right upper quadrant pain) while receiving therapy; when these symptoms occur, this and other suspect medications should be discontinued immediately and liver function tests and ALT and AST levels obtained",
                "Some patients may develop increased levels of urinary oxalate following treatment; cases of oxalate nephrolithiasis and oxalate nephropathy with renal failure reported; monitor renal function when prescribing therapy to patients at risk for renal impairment and use with caution in those with a history of hyperoxaluria or calcium oxalate nephrolithiasis; discontinue therapy in patients who develop oxalate nephropathy",
                "Substantial weight loss can increase risk of cholelithiasis",
                "Exclude organic causes of obesity (eg, hypothyroidism), before prescribing therapy",
                "May increase gastrointestinal events when taking a diet high on fat (>30% total daily calories from fat)",
                "Weight-loss may affect glycemic control in patients with diabetes mellitus; a reduction in dose of oral hypoglycemic medication (eg, sulfonylureas) or insulin may be required in some patients",
                "Avoid with anorexia nervosa or bulimia"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Cyclosporine: Should not be simultaneously coadministered with cyclosporine; can decrease cyclosporine exposure; to reduce chance of a drug-drug interaction, cyclosporine should be taken at least 3 hours before or after orlistat",
                        "Levothyroxine: Administer 4 hr apart; monitored for changes in thyroid function",
                        "Amiodarone PO: A pharmacokinetic study showed reduced amiodarone and desethylamiodarone systemic exposure when coadministered with orlistat",
                        "Antiepileptic drugs (AEDs): Convulsions reported with coadministration of AEDs and orlistat; monitor serum AED levels",
                        "Antiretroviral drugs: Loss of virological control has been reported in HIV-infected patients taking orlistat concomitantly with antiretroviral drugs; HIV RNA levels should be frequently monitored in patients taking orlistat and antiretrovirals drugs; if HIV viral load increases, discontinue orlistat",
                        "Warfarin",
                        "Vitamin K absorption may be decreased with orlistat",
                        "Reports of decreased prothrombin, increased INR, and unbalanced anticoagulant treatment resulting in change of hemostatic parameters have been with coadministration of orlistat and anticoagulants",
                        "Patients on chronic stable doses of warfarin or other anticoagulants who are prescribed orlistat should be monitored closely for coagulation parameters changes",
                        "Vitamin supplements",
                        "Orlistat may reduce absorption of some fat-soluble vitamins and beta-carotene",
                        "Instruct patient to take a multivitamin containing fat-soluble vitamins to ensure adequate nutrition",
                        "Take vitamin supplement at least 2 hr before or after taking orlistat, such as at bedtime"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "triheptanoin",
            "description": {
                "common": "orlistat decreases effects of triheptanoin by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of triheptanoin with orlistat may reduce exposure to the triheptanoin metabolite, heptanoate, and decrease the effects of triheptanoin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abacavir",
            "description": {
                "common": "orlistat will decrease the level or effect of abacavir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "orlistat decreases levels of acetazolamide by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "orlistat will decrease the level or effect of amiodarone by  Other (see comment). Use Caution/Monitor. Reduces absorption of amiodarone"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "orlistat will decrease the level or effect of atazanavir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "beta carotene",
            "description": {
                "common": "orlistat decreases levels of beta carotene by drug binding in GI tract. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "orlistat decreases levels of carbamazepine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "orlistat decreases levels of clobazam by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "orlistat decreases levels of clonazepam by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clorazepate",
            "description": {
                "common": "orlistat decreases levels of clorazepate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "orlistat decreases levels of cyclosporine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer cyclosporine 3 hours after orlistat ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "orlistat will decrease the level or effect of darunavir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "orlistat decreases levels of diazepam by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "didanosine",
            "description": {
                "common": "orlistat will decrease the level or effect of didanosine by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dolutegravir",
            "description": {
                "common": "orlistat will decrease the level or effect of dolutegravir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxercalciferol",
            "description": {
                "common": "orlistat decreases levels of doxercalciferol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "orlistat will decrease the level or effect of efavirenz by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir",
            "description": {
                "common": "orlistat will decrease the level or effect of elvitegravir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "emtricitabine",
            "description": {
                "common": "orlistat will decrease the level or effect of emtricitabine by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enfuvirtide",
            "description": {
                "common": "orlistat will decrease the level or effect of enfuvirtide by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "orlistat decreases levels of eslicarbazepine acetate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "orlistat decreases levels of ethosuximide by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethotoin",
            "description": {
                "common": "orlistat decreases levels of ethotoin by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "orlistat will decrease the level or effect of etravirine by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ezogabine",
            "description": {
                "common": "orlistat decreases levels of ezogabine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felbamate",
            "description": {
                "common": "orlistat decreases levels of felbamate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "orlistat will decrease the level or effect of fosamprenavir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "orlistat decreases levels of fosphenytoin by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gabapentin",
            "description": {
                "common": "orlistat decreases levels of gabapentin by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "orlistat will decrease the level or effect of indinavir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lacosamide",
            "description": {
                "common": "orlistat decreases levels of lacosamide by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lamivudine",
            "description": {
                "common": "orlistat will decrease the level or effect of lamivudine by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lamotrigine",
            "description": {
                "common": "orlistat decreases levels of lamotrigine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levetiracetam",
            "description": {
                "common": "orlistat decreases levels of levetiracetam by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "orlistat decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Risk of hypothyroidism. Separate by 4 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorazepam",
            "description": {
                "common": "orlistat decreases levels of lorazepam by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "orlistat will decrease the level or effect of maraviroc by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methsuximide",
            "description": {
                "common": "orlistat decreases levels of methsuximide by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "orlistat will decrease the level or effect of nelfinavir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "orlistat will decrease the level or effect of nevirapine by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "orlistat decreases levels of oxcarbazepine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paricalcitol",
            "description": {
                "common": "orlistat decreases levels of paricalcitol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perampanel",
            "description": {
                "common": "orlistat decreases levels of perampanel by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "orlistat decreases levels of phenobarbital by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "orlistat decreases levels of phenytoin by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pregabalin",
            "description": {
                "common": "orlistat decreases levels of pregabalin by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "orlistat decreases levels of primidone by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "raltegravir",
            "description": {
                "common": "orlistat will decrease the level or effect of raltegravir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rilpivirine",
            "description": {
                "common": "orlistat will decrease the level or effect of rilpivirine by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "orlistat will decrease the level or effect of ritonavir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rufinamide",
            "description": {
                "common": "orlistat decreases levels of rufinamide by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "orlistat will decrease the level or effect of saquinavir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stavudine",
            "description": {
                "common": "orlistat will decrease the level or effect of stavudine by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir AF",
            "description": {
                "common": "orlistat will decrease the level or effect of tenofovir AF by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "orlistat will decrease the level or effect of tenofovir DF by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiagabine",
            "description": {
                "common": "orlistat decreases levels of tiagabine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "orlistat will decrease the level or effect of tipranavir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "orlistat decreases levels of topiramate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "orlistat decreases levels of valproic acid by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vigabatrin",
            "description": {
                "common": "orlistat decreases levels of vigabatrin by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vitamin D",
            "description": {
                "common": "orlistat will decrease the level or effect of vitamin D by  Other (see comment). Use Caution/Monitor. When combination must be used, may consider administering vitamin D at least 2 hours before or after administration of orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "orlistat increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "orlistat will decrease the level or effect of zidovudine by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zonisamide",
            "description": {
                "common": "orlistat decreases levels of zonisamide by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "orlistat increases effects of atorvastatin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "orlistat increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ciprofibrate",
            "description": {
                "common": "orlistat increases effects of ciprofibrate by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibrate micronized",
            "description": {
                "common": "orlistat increases effects of fenofibrate micronized by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibric acid",
            "description": {
                "common": "orlistat increases effects of fenofibric acid by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "orlistat increases effects of fluvastatin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glimepiride",
            "description": {
                "common": "orlistat increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glipizide",
            "description": {
                "common": "orlistat increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glyburide",
            "description": {
                "common": "orlistat increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lovastatin",
            "description": {
                "common": "orlistat increases effects of lovastatin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pitavastatin",
            "description": {
                "common": "orlistat increases effects of pitavastatin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pravastatin",
            "description": {
                "common": "orlistat increases effects of pravastatin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rosuvastatin",
            "description": {
                "common": "orlistat increases effects of rosuvastatin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "simvastatin",
            "description": {
                "common": "orlistat increases effects of simvastatin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolazamide",
            "description": {
                "common": "orlistat increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "orlistat increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin A",
            "description": {
                "common": "orlistat decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin E",
            "description": {
                "common": "orlistat decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. May cause fat-soluble vitamin malabsorption. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin K1 (phytonadione)",
            "description": {
                "common": "orlistat decreases levels of vitamin K1 (phytonadione) by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Oily spotting",
            "percent": "5"
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "Fatty",
            "percent": null
        },
        {
            "name": "oily stool",
            "percent": null
        },
        {
            "name": "Increased defecation",
            "percent": null
        },
        {
            "name": "Fecal incontinence",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Reduced absorption of fat soluble vitamins and beta",
            "percent": null
        },
        {
            "name": "carotene",
            "percent": null
        },
        {
            "name": "Liver failure",
            "percent": null
        },
        {
            "name": "Oxalate nephropathy",
            "percent": null
        },
        {
            "name": "Leukocytoclastic vasculitis",
            "percent": null
        }
    ]
}